-
1
-
-
33646491588
-
Nonnarcotic analgesics and hypertension
-
Gaziano JM. Nonnarcotic analgesics and hypertension. Am. J. Cardiol. 97, 10-16 (2006)
-
(2006)
Am. J. Cardiol.
, vol.97
, pp. 10-16
-
-
Gaziano, J.M.1
-
2
-
-
0036047916
-
Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors
-
Peura DA. Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors. Cleve. Clin. J. Med. 69(Suppl. 1), SI31-SI39 (2002)
-
(2002)
Cleve. Clin. J. Med.
, vol.69
, Issue.SUPPL. 1
-
-
Peura, D.A.1
-
3
-
-
20044389684
-
Pharmacology in rehabilitation: Nonsteroidal anti-inflammatory agents
-
Biederman RE. Pharmacology in rehabilitation: nonsteroidal anti-inflammatory agents. J. Orthop. Sports Phys. Ther. 35(6), 356-367 (2005)
-
(2005)
J. Orthop. Sports Phys. Ther.
, vol.35
, Issue.6
, pp. 356-367
-
-
Biederman, R.E.1
-
4
-
-
74049091834
-
NSAID prescribing precautions
-
Risser A, Donovan D, Heintzman J, Page T. NSAID prescribing precautions. Am. Fam. Physician 80(12), 1371-1378 (2009)
-
(2009)
Am. Fam. Physician
, vol.80
, Issue.12
, pp. 1371-1378
-
-
Risser, A.1
Donovan, D.2
Heintzman, J.3
Page, T.4
-
5
-
-
33750485846
-
GI risk and risk factors of NSAIDs
-
Laine L. GI risk and risk factors of NSAIDs. J. Cardiovasc. Pharmacol. 47(Suppl. 1), S60-S66 (2006)
-
(2006)
J. Cardiovasc. Pharmacol.
, vol.47
, Issue.SUPPL. 1
-
-
Laine, L.1
-
6
-
-
32244441631
-
NSAID-associated adverse effects and acid control aids to prevent them: A review of current treatment options
-
Naesdal J, Brown K. NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options. Drug Saf. 29(2), 119-132 (2006)
-
(2006)
Drug Saf.
, vol.29
, Issue.2
, pp. 119-132
-
-
Naesdal, J.1
Brown, K.2
-
7
-
-
61949239030
-
Guidelines for prevention of NSAID-related ulcer complications
-
Lanza FL, Chan FKL, Quigley EMM. Guidelines for prevention of NSAID-related ulcer complications. Am. J. Gastroenterol. 104(3), 728-738 (2009)
-
(2009)
Am. J. Gastroenterol.
, vol.104
, Issue.3
, pp. 728-738
-
-
Lanza, F.L.1
Fkl, C.2
Emm, Q.3
-
8
-
-
25644460012
-
NSAID-associated deaths: The rise and fall of NSAID-associated GI mortality
-
Cryer B. NSAID-associated deaths: the rise and fall of NSAID-associated GI mortality. Am. J. Gastroenterol. 100, 1694-1695 (2005)
-
(2005)
Am. J. Gastroenterol.
, vol.100
, pp. 1694-1695
-
-
Cryer, B.1
-
9
-
-
2342541844
-
Nonselective nonaspirin nonsteroidal anti-inflammatory drugs and gastrointestinal bleeding: Relative and absolute risk estimates from recent epidemiologic studies
-
Tarone RE, Blot WJ, McLaughlin JK. Nonselective nonaspirin nonsteroidal anti-inflammatory drugs and gastrointestinal bleeding: relative and absolute risk estimates from recent epidemiologic studies. Am. J. Ther. 11(1), 17-25 (2004)
-
(2004)
Am. J. Ther.
, vol.11
, Issue.1
, pp. 17-25
-
-
Tarone, R.E.1
Blot, W.J.2
McLaughlin, J.K.3
-
10
-
-
0032931328
-
Epidemiology of NSAID induced gastrointestinal complications
-
Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J. Rheumatol. 26(Suppl.), 18-24 (1999)
-
(1999)
J. Rheumatol.
, vol.26
, Issue.SUPPL.
, pp. 18-24
-
-
Singh, G.1
Triadafilopoulos, G.2
-
11
-
-
67749084746
-
Mortality with upper gastrointestinal bleeding and perforation: Effects of time and NSAID use
-
Straube S, Tramr MR, Moore RA, et al. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterol. 9, 41 (2009)
-
(2009)
BMC Gastroenterol.
, vol.9
, pp. 41
-
-
Straube, S.1
Tramr, M.R.2
Moore, R.A.3
-
12
-
-
85046588922
-
Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice
-
Lanas A, García-Rodríguez LA, Polo-Tomás M, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am. J. Gastroenterol. 104(7), 1633-1641 (2009)
-
(2009)
Am. J. Gastroenterol.
, vol.104
, Issue.7
, pp. 1633-1641
-
-
Lanas, A.1
García-Rodríguez, L.A.2
Polo-Tomás, M.3
-
13
-
-
0033856811
-
Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: Retrospective cohort study of an elderly population
-
Rahme E, Joseph L, Kong SX, et al. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population. Arthritis Rheum. 43(4), 917-924 (2000)
-
(2000)
Arthritis Rheum.
, vol.43
, Issue.4
, pp. 917-924
-
-
Rahme, E.1
Joseph, L.2
Kong, S.X.3
-
14
-
-
0029738533
-
Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs
-
Smalley WE, Griffin MR, Fought RL, et al. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. J. Gen. Intern. Med. 11(8), 461-469 (1996)
-
(1996)
J. Gen. Intern. Med.
, vol.11
, Issue.8
, pp. 461-469
-
-
Smalley, W.E.1
Griffin, M.R.2
Fought, R.L.3
-
15
-
-
7044253346
-
Prevention of nonsteroidal anti-inflammatory drug-associated gastrointestinal symptoms and ulcer complications
-
Peura DA. Prevention of nonsteroidal anti-inflammatory drug-associated gastrointestinal symptoms and ulcer complications. Am. J. Med. 117(Suppl. 5A), S63-S71 (2004)
-
(2004)
Am. J. Med.
, vol.117
, Issue.SUPPL. 5A
-
-
Peura, D.A.1
-
16
-
-
83455208965
-
NSAID-associated GI complications: Available management options and identification of high-risk patients
-
Abdrabbo MK, Peura DA. NSAID-associated GI complications: available management options and identification of high-risk patients. Gastroenterl. Endo. News 2, 65-68 (2004)
-
(2004)
Gastroenterl. Endo. News
, vol.2
, pp. 65-68
-
-
Abdrabbo, M.K.1
Peura, D.A.2
-
17
-
-
55349127823
-
First international working party on gastrointestinal and cardiovascular effects of nonsteroidal anti-inflammatory drugs and anti-platelet agents. Management of patients on nonsteroidal anti-inflammatory drugs: A clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents
-
Chan FK, Abraham NS, Scheiman JM, et al. First international working party on gastrointestinal and cardiovascular effects of nonsteroidal anti-inflammatory drugs and anti-platelet agents. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am. J. Gastroenterol. 103, 2908-2918 (2008)
-
(2008)
Am. J. Gastroenterol.
, vol.103
, pp. 2908-2918
-
-
Chan, F.K.1
Abraham, N.S.2
Scheiman, J.M.3
-
18
-
-
77953939679
-
The role of acetaminophen in the treatment of osteoarthritis
-
Flood J. The role of acetaminophen in the treatment of osteoarthritis. Am. J. Manag. Care 16(Suppl. Management), S48-S54 (2010)
-
(2010)
Am. J. Manag. Care
, vol.16
, Issue.SUPPL. MANAGEMENT
-
-
Flood, J.1
-
19
-
-
3242685960
-
Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials
-
Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann. Rheum. Dis. 63(8), 901-907 (2004)
-
(2004)
Ann. Rheum. Dis.
, vol.63
, Issue.8
, pp. 901-907
-
-
Zhang, W.1
Jones, A.2
Doherty, M.3
-
21
-
-
0036985907
-
Prevention of NSAID-induced gastroduodenal ulcers
-
Update CD002296
-
Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst. Rev. 4, Update CD002296 (2002)
-
(2002)
Cochrane Database Syst. Rev.
, vol.4
-
-
Rostom, A.1
Dube, C.2
Wells, G.3
-
22
-
-
33751306751
-
A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: A systematic review with economic modeling
-
iii-iv, xi-xiii
-
Brown T J, Hooper L, Elliott R A, et al. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modeling. Health Technol. Assess. 10(38), iii-iv, xi-xiii, 1-183 (2006)
-
(2006)
Health Technol. Assess.
, vol.10
, Issue.38
, pp. 1-183
-
-
Brown, T.J.1
Hooper, L.2
Elliott, R.A.3
-
23
-
-
0032510378
-
Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group
-
Hawkey CJ, Karrasch JA, Szczepañski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. NEJM 338(11), 727-734 (1998)
-
(1998)
NEJM
, vol.338
, Issue.11
, pp. 727-734
-
-
Hawkey, C.J.1
Karrasch, J.A.2
Szczepañski, L.3
-
25
-
-
7044232909
-
The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: Systematic review
-
Hooper L, Brown TJ, Elliott R, et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 329(7472), 948 (2004)
-
(2004)
BMJ
, vol.329
, Issue.7472
, pp. 948
-
-
Hooper, L.1
Brown, T.J.2
Elliott, R.3
-
26
-
-
33847328353
-
Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants
-
Lanas A, García-Rodríguez LA, Arroyo MT, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am. J. Gastroenterol. 102(3), 507-515 (2007)
-
(2007)
Am. J. Gastroenterol.
, vol.102
, Issue.3
, pp. 507-515
-
-
Lanas, A.1
García-Rodríguez, L.A.2
Arroyo, M.T.3
-
27
-
-
65349111293
-
The drug-drug interaction between proton pump inhibitors and clopidogrel
-
Lau WC, Gurbel PA. The drug-drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180(7), 699-700 (2009)
-
(2009)
CMAJ
, vol.180
, Issue.7
, pp. 699-700
-
-
Lau, W.C.1
Gurbel, P.A.2
-
28
-
-
70249139788
-
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: An analysis of two randomised trials
-
O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 374, 989-997 (2009)
-
(2009)
Lancet
, vol.374
, pp. 989-997
-
-
O'Donoghue, M.L.1
Braunwald, E.2
Antman, E.M.3
-
29
-
-
79955014648
-
Impact of concomitant use of proton-pump inhibitors and thienopyridine derivatives on the antiplatelet effects
-
Tsukahara K, Kimura K, Morita S, et al. Impact of concomitant use of proton-pump inhibitors and thienopyridine derivatives on the antiplatelet effects. J. Cardiol. 57, 275-282 (2011)
-
(2011)
J. Cardiol.
, vol.57
, pp. 275-282
-
-
Tsukahara, K.1
Kimura, K.2
Morita, S.3
-
30
-
-
79955057805
-
Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: A randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction
-
Fontes-Carvalho R, Albuquerque A, Araújo C, et al. Omeprazole, but not pantoprazole, reduces the antiplatelet effect of clopidogrel: a randomized clinical crossover trial in patients after myocardial infarction evaluating the clopidogrel-PPIs drug interaction. Eur. J. Gastroenterol. Hepatol. 23, 396-404 (2011)
-
(2011)
Eur. J. Gastroenterol. Hepatol.
, vol.23
, pp. 396-404
-
-
Fontes-Carvalho, R.1
Albuquerque, A.2
Araújo, C.3
-
31
-
-
64849087438
-
Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel
-
Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb. Haemost. 101, 714-719 (2009)
-
(2009)
Thromb. Haemost.
, vol.101
, pp. 714-719
-
-
Sibbing, D.1
Morath, T.2
Stegherr, J.3
-
32
-
-
77953790583
-
Proton pump inhibitors and clopidogrel: Is it a significant drug interaction?
-
Oyetayo OO, Talbert RL. Proton pump inhibitors and clopidogrel: is it a significant drug interaction? Expert Opin. Drug Saf. 9, 593-602 (2010)
-
(2010)
Expert Opin. Drug Saf.
, vol.9
, pp. 593-602
-
-
Oyetayo, O.O.1
Talbert, R.L.2
-
33
-
-
79952259717
-
Review article: Proton pump inhibitors with clopidogrel-evidence for and against a clinically-important interaction
-
Disney BR, Watson RD, Blann AD, et al. Review article: proton pump inhibitors with clopidogrel-evidence for and against a clinically-important interaction. Aliment. Pharmacol. Ther. 33, 758-767 (2011)
-
(2011)
Aliment. Pharmacol. Ther.
, vol.33
, pp. 758-767
-
-
Disney, B.R.1
Watson, R.D.2
Blann, A.D.3
-
34
-
-
78751681251
-
Clopidogrel and proton pump inhibitors: A clinically meaningful interaction?
-
Gerhard T. Clopidogrel and proton pump inhibitors: a clinically meaningful interaction? Pharmacoepidemiol. Drug Saf. 20, 214-218 (2011)
-
(2011)
Pharmacoepidemiol. Drug Saf.
, vol.20
, pp. 214-218
-
-
Gerhard, T.1
-
35
-
-
78149487926
-
Clopidogrel with or without omeprazole in coronary artery disease
-
COGENT Investigators
-
Bhatt DL, Cryer BL, Contant CF, et al. COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N. Engl. J. Med. 363, 1909-1917 (2010)
-
(2010)
N. Engl. J. Med.
, vol.363
, pp. 1909-1917
-
-
Bhatt, D.L.1
Cryer, B.L.2
Contant, C.F.3
-
36
-
-
78349244351
-
Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: A systematic review and meta-analysis
-
Siller-Matula JM, Jilma B, Schrör K, et al. Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. J. Thromb. Haemost. 8, 2624-2641 (2010)
-
(2010)
J. Thromb. Haemost.
, vol.8
, pp. 2624-2641
-
-
Siller-Matula, J.M.1
Jilma, B.2
Schrör, K.3
-
37
-
-
49749141653
-
Use of proton pump inhibitors and risk of osteoporosis-related fractures
-
Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 179(4), 319-326 (2008)
-
(2008)
CMAJ
, vol.179
, Issue.4
, pp. 319-326
-
-
Targownik, L.E.1
Lix, L.M.2
Metge, C.J.3
-
38
-
-
68049115736
-
Drug interaction between clopidogrel and proton pump inhibitors
-
Khalique SC, Cheng-Lai A. Drug interaction between clopidogrel and proton pump inhibitors. Cardio. Rev. 17(4), 198-200 (2009)
-
(2009)
Cardio. Rev.
, vol.17
, Issue.4
, pp. 198-200
-
-
Khalique, S.C.1
Cheng-Lai, A.2
-
39
-
-
77957327211
-
Safety of proton pump inhibitor exposure
-
Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology 139(4), 1115-1127 (2010)
-
(2010)
Gastroenterology
, vol.139
, Issue.4
, pp. 1115-1127
-
-
Yang, Y.X.1
Metz, D.C.2
-
40
-
-
34447092493
-
Gastrointestinal safety of cyclooxygenase-2 inhibitors: A Cochrane collaboration systematic review
-
Rostom A, Muir K, Dubé C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane collaboration systematic review. Clin. Gastroenterol. Hepatol. 5(7), 818-828, (2007)
-
(2007)
Clin. Gastroenterol. Hepatol.
, vol.5
, Issue.7
, pp. 818-828
-
-
Rostom, A.1
Muir, K.2
Dubé, C.3
-
41
-
-
80053307147
-
Cardiovascular risk with non-steroidal anti-inflammatory drugs: Systematic review of population-based controlled observational studies
-
McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 8, e1001098 (2011)
-
(2011)
PLoS Med.
, vol.8
-
-
McGettigan, P.1
Henry, D.2
-
43
-
-
0346433965
-
Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs
-
Sturkenboom MC, Burke T, Tangelder M, et al. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment. Pharmacol. Ther. 18(11-12), 1137-1147 (2003)
-
(2003)
Aliment. Pharmacol. Ther.
, vol.18
, Issue.11-12
, pp. 1137-1147
-
-
Sturkenboom, M.C.1
Burke, T.2
Tangelder, M.3
-
44
-
-
0031881092
-
Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: A randomized, placebo controlled trial. Arthrotec Osteoarthritis Study Group
-
Bocanegra TS, Weaver AL, Tindall EA, et al. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec Osteoarthritis Study Group. J. Rheumatol. 25(8), 1602-1611 (1998)
-
(1998)
J. Rheumatol.
, vol.25
, Issue.8
, pp. 1602-1611
-
-
Bocanegra, T.S.1
Weaver, A.L.2
Tindall, E.A.3
-
45
-
-
27644531878
-
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications
-
Lai KC, Chu KM, Hui WM, et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am. J. Med. 118(11), 1271-1278 (2005)
-
(2005)
Am. J. Med.
, vol.118
, Issue.11
, pp. 1271-1278
-
-
Lai, K.C.1
Chu, K.M.2
Hui, W.M.3
-
46
-
-
77954331288
-
Clinical trial: The incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone
-
Goldstein JL, Hochberg MC, Fort JG, et al. Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone. Aliment. Pharmacol. Ther. 32(3), 401-413 (2010)
-
(2010)
Aliment. Pharmacol. Ther.
, vol.32
, Issue.3
, pp. 401-413
-
-
Goldstein, J.L.1
Hochberg, M.C.2
Fort, J.G.3
-
47
-
-
77955282952
-
Significant reduction in upper gastrointestinal (UGI) ulcers with HZT-501, a single-tablet combination of ibuprofen-famotidine, the Reduce 1 and 2 Trials
-
Weinblatt ME, Schiff M, Genovese M, et al. Significant reduction in upper gastrointestinal (UGI) ulcers with HZT-501, a single-tablet combination of ibuprofen-famotidine, the Reduce 1 and 2 Trials. Ann. Rheum. Dis. 68(Suppl. 3), 704 (2009)
-
(2009)
Ann. Rheum. Dis.
, vol.68
, Issue.SUPPL. 3
, pp. 704
-
-
Weinblatt, M.E.1
Schiff, M.2
Genovese, M.3
-
48
-
-
0017002526
-
Evaluation of analgesic action and efficacy of antirheumatic drugs. Study of 10 drugs in 684 patients with rheumatoid arthritis
-
Lee P, Anderson JA, Miller J, et al. Evaluation of analgesic action and efficacy of antirheumatic drugs. Study of 10 drugs in 684 patients with rheumatoid arthritis. J. Rheumatol. 3(3), 283-294 (1976)
-
(1976)
J. Rheumatol.
, vol.3
, Issue.3
, pp. 283-294
-
-
Lee, P.1
Anderson, J.A.2
Miller, J.3
-
49
-
-
0002656782
-
Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs
-
García Rodríguez LA, Cattaruzzi C, Troncon MG, et al. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch. Intern. Med. 158(1), 33-39 (1998)
-
(1998)
Arch. Intern. Med.
, vol.158
, Issue.1
, pp. 33-39
-
-
García Rodríguez, L.A.1
Cattaruzzi, C.2
Troncon, M.G.3
-
50
-
-
0028353941
-
Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs
-
Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 343(8905), 1075-1078 (1994)
-
(1994)
Lancet
, vol.343
, Issue.8905
, pp. 1075-1078
-
-
Langman, M.J.1
Weil, J.2
Wainwright, P.3
-
51
-
-
0037393479
-
Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs
-
Henry D, McGettigan P. Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs. Int. J. Clin. Pract. Suppl. (135), 43-49 (2003)
-
(2003)
Int. J. Clin. Pract. Suppl.
, vol.135
, pp. 43-49
-
-
Henry, D.1
McGettigan, P.2
-
52
-
-
0035168347
-
Determinants of impaired renal function with use of nonsteroidal anti-inflammatory drugs: The importance of half-life and other medications
-
Stürmer T, Erb A, Keller F, et al. Determinants of impaired renal function with use of nonsteroidal anti-inflammatory drugs: the importance of half-life and other medications. Am. J. Med. 111(7), 521-527 (2001)
-
(2001)
Am. J. Med.
, vol.111
, Issue.7
, pp. 521-527
-
-
Stürmer, T.1
Erb, A.2
Keller, F.3
-
53
-
-
0034159817
-
Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons
-
Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am. J. Epidemiology 151(5), 488-496 (2000)
-
(2000)
Am. J. Epidemiology
, vol.151
, Issue.5
, pp. 488-496
-
-
Griffin, M.R.1
Yared, A.2
Ray, W.A.3
-
54
-
-
0029851015
-
Ibuprofen and diclofenac sodium in the treatment of osteoarthritis: A comparative trial of two once-daily sustained-release NSAID formulations
-
Baumgartner H, Schwarz HA, Blum W, et al. Ibuprofen and diclofenac sodium in the treatment of osteoarthritis: a comparative trial of two once-daily sustained-release NSAID formulations. Curr. Med. Res. Opin. 13(8), 435-444 (1996)
-
(1996)
Curr. Med. Res. Opin.
, vol.13
, Issue.8
, pp. 435-444
-
-
Baumgartner, H.1
Schwarz, H.A.2
Blum, W.3
-
55
-
-
4344646701
-
The IPSO study: Ibuprofen, paracetamol study in osteoarthritis. A randomised comparative clinical study comparing the efficacy and safety of ibuprofen and paracetamol analgesic treatment of osteoarthritis of the knee or hip
-
Boureau F, Schneid H, Zeghari N, et al. The IPSO study: ibuprofen, paracetamol study in osteoarthritis. A randomised comparative clinical study comparing the efficacy and safety of ibuprofen and paracetamol analgesic treatment of osteoarthritis of the knee or hip. Ann. Rheum. Dis. 63(9), 1028-1034 (2004)
-
(2004)
Ann. Rheum. Dis.
, vol.63
, Issue.9
, pp. 1028-1034
-
-
Boureau, F.1
Schneid, H.2
Zeghari, N.3
-
56
-
-
0034717664
-
A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/ibuprofen Comparator Study Group
-
Day R, Morrison B, Luza A, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/ibuprofen Comparator Study Group. Arch. Intern. Med. 160(12), 1781-1787 (2000)
-
(2000)
Arch. Intern. Med.
, vol.160
, Issue.12
, pp. 1781-1787
-
-
Day, R.1
Morrison, B.2
Luza, A.3
-
57
-
-
35748934466
-
A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis
-
Puopolo A, Boice JA, Fidelholtz JL, et al. A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. Osteoarthritis Cartilage 15(12), 1348-1356 (2007)
-
(2007)
Osteoarthritis Cartilage
, vol.15
, Issue.12
, pp. 1348-1356
-
-
Puopolo, A.1
Boice, J.A.2
Fidelholtz, J.L.3
-
58
-
-
16344383840
-
Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial
-
Wiesenhutter CW, Boice JA, Ko A, et al. Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Mayo. Clin. Proc. 80(4), 470-479 (2005)
-
(2005)
Mayo. Clin. Proc.
, vol.80
, Issue.4
, pp. 470-479
-
-
Wiesenhutter, C.W.1
Boice, J.A.2
Ko, A.3
-
59
-
-
0027538286
-
Efficacy of famotidine in the healing of active benign gastric ulceration: Comparison of nonsteroidal anti-inflammatory-or aspirin-induced gastric ulcer and idiopathic gastric ulceration. Long Island Jewish Medical Center Acid-Peptic Study Group
-
Bank S, Blumstein M, Greenberg R, et al. Efficacy of famotidine in the healing of active benign gastric ulceration: comparison of nonsteroidal anti-inflammatory-or aspirin-induced gastric ulcer and idiopathic gastric ulceration. Long Island Jewish Medical Center Acid-Peptic Study Group. Clin. Ther. 15(1), 36-45 (1993)
-
(1993)
Clin. Ther.
, vol.15
, Issue.1
, pp. 36-45
-
-
Bank, S.1
Blumstein, M.2
Greenberg, R.3
-
60
-
-
9344236529
-
Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs
-
Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 334(22), 1435-1439 (1996)
-
(1996)
N. Engl. J. Med.
, vol.334
, Issue.22
, pp. 1435-1439
-
-
Taha, A.S.1
Hudson, N.2
Hawkey, C.J.3
-
61
-
-
0030961530
-
Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration
-
Hudson N, Taha A, Russell R, et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology 112(6), 1817-1822 (1997)
-
(1997)
Gastroenterology
, vol.112
, Issue.6
, pp. 1817-1822
-
-
Hudson, N.1
Taha, A.2
Russell, R.3
-
62
-
-
67649861111
-
Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): A Phase III, randomised, double-blind, placebo-controlled trial
-
Taha AS, McCloskey C, Prasad R, et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a Phase III, randomised, double-blind, placebo-controlled trial. Lancet 374(9684), 119-125 (2009)
-
(2009)
Lancet
, vol.374
, Issue.9684
, pp. 119-125
-
-
Taha, A.S.1
McCloskey, C.2
Prasad, R.3
-
63
-
-
18144368022
-
-
Motrin® McNeil Consumer Pharmaceuticals Co., Fort Washington, PA, USA
-
Motrin®, prescribing information, McNeil Consumer Pharmaceuticals Co., Fort Washington, PA, USA (2003)
-
(2003)
Prescribing Information
-
-
-
64
-
-
18144368022
-
-
Pepcid® McNeil Consumer Pharmaceuticals Co., Fort Washington, PA, USA
-
Pepcid®, prescribing information, McNeil Consumer Pharmaceuticals Co., Fort Washington, PA, USA (2008)
-
(2008)
Prescribing Information
-
-
-
65
-
-
0029866402
-
Introduction: Mechanism of action of NSAIDs
-
Vane JR. Introduction: mechanism of action of NSAIDs. Br. J. Rheumatol. 35(Suppl. 1), 1-3 (1996)
-
(1996)
Br. J. Rheumatol.
, vol.35
, Issue.SUPPL. 1
, pp. 1-3
-
-
Vane, J.R.1
-
66
-
-
0034468514
-
Pharmacological basis for the therapy of pain and inflammation with nonsteroidal anti-inflammatory drugs
-
Steinmeyer J. Pharmacological basis for the therapy of pain and inflammation with nonsteroidal anti-inflammatory drugs. Arthritis Res. 2(5), 379-85 (2000)
-
(2000)
Arthritis Res.
, vol.2
, Issue.5
, pp. 379-85
-
-
Steinmeyer, J.1
-
67
-
-
75749113330
-
Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: Bridging a gap between clinical trials and clinical practice
-
Moore RA, Moore OA, Derry S, et al. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann. Rheum. Dis. 69(2), 374-379 (2010)
-
(2010)
Ann. Rheum. Dis.
, vol.69
, Issue.2
, pp. 374-379
-
-
Moore, R.A.1
Moore, O.A.2
Derry, S.3
-
68
-
-
0024462492
-
Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases
-
Langtry HD, Grant SM, Goa KL. Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 38(4), 551-590 (1989)
-
(1989)
Drugs
, vol.38
, Issue.4
, pp. 551-590
-
-
Langtry, H.D.1
Grant, S.M.2
Goa, K.L.3
-
69
-
-
0023625420
-
Single bedtime dose of famotidine: Assessment of its antisecretory action by 24-hour intragastric pH monitoring
-
Savarino V, Picciotto A, Magnolia MR, et al. Single bedtime dose of famotidine: assessment of its antisecretory action by 24-hour intragastric pH monitoring. J. Clin. Pharmacol. 27(10), 790-793 (1987)
-
(1987)
J. Clin. Pharmacol.
, vol.27
, Issue.10
, pp. 790-793
-
-
Savarino, V.1
Picciotto, A.2
Magnolia, M.R.3
-
70
-
-
83455183251
-
Famotidine (FAM) administered orally three times daily (tid) produces better gastric acid suppression and control than does twice daily (bid) administration of the same total daily dose
-
Chicago IL USA 30 May-4 June Abstract T1971
-
Tidmarsh G, Rodriguez SB. Famotidine (FAM) administered orally three times daily (tid) produces better gastric acid suppression and control than does twice daily (bid) administration of the same total daily dose. Presented at: Digestive Disease Week. Chicago, IL, USA, 30 May-4 June 2009 (Abstract T1971)
-
(2009)
Digestive Disease Week
-
-
Tidmarsh, G.1
Rodriguez, S.B.2
-
71
-
-
83455208961
-
HZT-501, a novel combination of ibuprofen (IBU) and famotidine (FAM), provides pharmacokinetics comparable to that of commercially available IBU and FAM in a patient-friendly dosing form: Evaluation in healthy and renally-impaired subjects
-
Chicago, IL, USA, 30 May-4 June Abstract T1974
-
Tidmarsh G, Rodriguez SB. HZT-501, a novel combination of ibuprofen (IBU) and famotidine (FAM), provides pharmacokinetics comparable to that of commercially available IBU and FAM in a patient-friendly dosing form: evaluation in healthy and renally-impaired subjects. Presented at: Digestive Disease Week. Chicago, IL, USA, 30 May-4 June 2009 (Abstract T1974)
-
(2009)
Digestive Disease Week
-
-
Tidmarsh, G.1
Rodriguez, S.B.2
-
73
-
-
0034785912
-
Nephrotoxicity in the elderly due to co-prescription of angiotensin converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs
-
Adhiyaman V, Asghar M, Oke A, White AD, Shah IU. Nephrotoxicity in the elderly due to co-prescription of angiotensin converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs. J. R. Soc. Med. 94, 512-514 (2001)
-
(2001)
J. R. Soc. Med.
, vol.94
, pp. 512-514
-
-
Adhiyaman, V.1
Asghar, M.2
Oke, A.3
White, A.D.4
Shah, I.U.5
-
74
-
-
18144384396
-
Nonsteroidal anti-inflammatory drugs and hepatic toxicity: A systematic review of randomized controlled trials in arthritis patients
-
Rostom A, Goldkind L, Laine L. Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients. Clin. Gastroenterol. Hepatol. 3(5), 489-498 (2005)
-
(2005)
Clin. Gastroenterol. Hepatol.
, vol.3
, Issue.5
, pp. 489-498
-
-
Rostom, A.1
Goldkind, L.2
Laine, L.3
-
75
-
-
83455233525
-
Independent predictors for the development of upper gastrointestinal ulcers: Results from two 24-week double-blind trials of a single-tablet combination of ibuprofen-famotidine vs. ibuprofen alone (REDUCE-1 and 2)
-
Chicago IL USA 30 May-4 June Abstract 407
-
Laine L, Schiff M, Genovese M, et al. Independent predictors for the development of upper gastrointestinal ulcers: results from two 24-week double-blind trials of a single-tablet combination of ibuprofen-famotidine vs. ibuprofen alone (REDUCE-1 and 2). Digestive Disease Week. Chicago, IL, USA, 30 May-4 June 2009 (Abstract 407)
-
(2009)
Digestive Disease Week
-
-
Laine, L.1
Schiff, M.2
Genovese, M.3
-
76
-
-
83455183249
-
Efficacy, safety and tolerability of HZT-501, including users of low-dose aspirin, a single-tablet combination of ibuprofen-famotidine: Results of two Phase 3 trials
-
Atlanta, GA , USA, 7-11 November
-
Weinblatt ME, Genovese MC, Kivitz AJ, et al. Efficacy, safety and tolerability of HZT-501, including users of low-dose aspirin, a single-tablet combination of ibuprofen-famotidine: results of two Phase 3 trials. Presented at: American College of Rheumatology Annual Scientific Meeting. Atlanta, GA , USA, 7-11 November 2010
-
(2010)
American College of Rheumatology Annual Scientific Meeting
-
-
Weinblatt, M.E.1
Genovese, M.C.2
Kivitz, A.J.3
-
77
-
-
0029848806
-
The tolerability and safety profile of famotidine
-
Howden CW, Tytgat GN. The tolerability and safety profile of famotidine. Clin. Ther. 18(1), 36-54 (1996)
-
(1996)
Clin. Ther.
, vol.18
, Issue.1
, pp. 36-54
-
-
Howden, C.W.1
Tytgat, G.N.2
-
78
-
-
83455183248
-
Long-term safety of an NSAID with built-in gastroprotection for treatment of pain and inflammation related to OA and RA: Results from a one-year safety trial of a single-tablet combination of ibuprofen-famotidine vs ibuprofen alone
-
Schiff MH, Genovese MC, Kivitz MC, et al. Long-term safety of an NSAID with built-in gastroprotection for treatment of pain and inflammation related to OA and RA: results from a one-year safety trial of a single-tablet combination of ibuprofen-famotidine vs ibuprofen alone. Arthritis Rheum. 62(Suppl. 10), 946 (2009)
-
(2009)
Arthritis Rheum.
, vol.62
, Issue.SUPPL. 10
, pp. 946
-
-
Schiff, M.H.1
Genovese, M.C.2
Kivitz, M.C.3
-
79
-
-
79954485360
-
An overview of clinical pharmacology of ibuprofen
-
Bushra R, Aslam N. An overview of clinical pharmacology of ibuprofen. Oman Med. J. 25(3), 155-161 (2010)
-
(2010)
Oman Med. J.
, vol.25
, Issue.3
, pp. 155-161
-
-
Bushra, R.1
Aslam, N.2
-
80
-
-
0343472105
-
Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation
-
Gutthann SP, García Rodríguez LA, Raiford DS. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 8(1), 18-24 (1997)
-
(1997)
Epidemiology
, vol.8
, Issue.1
, pp. 18-24
-
-
Gutthann, S.P.1
García Rodríguez, L.A.2
Raiford, D.S.3
-
81
-
-
0032066149
-
NSAID induced gastrointestinal complications: The ARAMIS perspective-1997. Arthritis, Rheumatism, and Aging Medical Information System
-
Singh G, Rosen RD. NSAID induced gastrointestinal complications: the ARAMIS perspective-1997. Arthritis, Rheumatism, and Aging Medical Information System. J. Rheumatol. 51(Suppl.), 8-16 (1998)
-
(1998)
J. Rheumatol.
, vol.51
, Issue.SUPPL.
, pp. 8-16
-
-
Singh, G.1
Rosen, R.D.2
-
82
-
-
0027494252
-
Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs
-
Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann. Intern. Med. 119, 257-262 (1993)
-
(1993)
Ann. Intern. Med.
, vol.119
, pp. 257-262
-
-
Graham, D.Y.1
White, R.H.2
Moreland, L.W.3
-
83
-
-
33646493162
-
Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: A meta-analysis
-
Spiegel BMR, Farid M, Dulai GS, et al. Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis. Am. J. Med. 119(5), e27-e36 (2006)
-
(2006)
Am. J. Med.
, vol.119
, Issue.5
-
-
Bmr, S.1
Farid, M.2
Dulai, G.S.3
-
84
-
-
34250179723
-
Fixed-dose combinations improve medication compliance: A meta-analysis
-
Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am. J. Med. 120(8), 713-719 (2007)
-
(2007)
Am. J. Med.
, vol.120
, Issue.8
, pp. 713-719
-
-
Bangalore, S.1
Kamalakkannan, G.2
Parkar, S.3
-
86
-
-
71849097187
-
Chronic musculoskeletal pain and the occurrence of falls in an older population
-
Leveille SG, Jones RN, Kiely DK, et al. Chronic musculoskeletal pain and the occurrence of falls in an older population. JAMA 302(20), 2214-2221 (2009)
-
(2009)
JAMA
, vol.302
, Issue.20
, pp. 2214-2221
-
-
Leveille, S.G.1
Jones, R.N.2
Kiely, D.K.3
-
87
-
-
38949165402
-
Age-related prevalence of facet-joint involvement in chronic neck and low back pain
-
Manchikanti L, Manchikanti KN, Cash KA, et al. Age-related prevalence of facet-joint involvement in chronic neck and low back pain. Pain Physician 11(1), 67-75 (2008)
-
(2008)
Pain Physician
, vol.11
, Issue.1
, pp. 67-75
-
-
Manchikanti, L.1
Manchikanti, K.N.2
Cash, K.A.3
-
88
-
-
0036347820
-
Chronic neck and shoulder pain, age, and working conditions: Longitudinal results from a large random sample in France
-
Cassou B, Derriennic F, Monfort C, et al. Chronic neck and shoulder pain, age, and working conditions: longitudinal results from a large random sample in France. Occup. Environ. Med. 59(8), 537-544 (2002)
-
(2002)
Occup. Environ. Med.
, vol.59
, Issue.8
, pp. 537-544
-
-
Cassou, B.1
Derriennic, F.2
Monfort, C.3
-
89
-
-
77952841800
-
Identification of NSAID users at risk for gastrointestinal complications: A systematic review of current guidelines and consensus agreements
-
Tielemans MM, Eikendal T, Jansen JB, et al. Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements. Drug Saf. 33(6), 443-453 (2010)
-
(2010)
Drug Saf.
, vol.33
, Issue.6
, pp. 443-453
-
-
Tielemans, M.M.1
Eikendal, T.2
Jansen, J.B.3
-
90
-
-
0002085896
-
Non-steroidal anti-inflammatory drugs and ulcer complications: A risk factor analysis for clinical decision-making
-
Hansen JM, Hallas J, Lauritsen JM, et al. Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making. Scand. J. Gastroenterol. 31(2), 126-130 (1996)
-
(1996)
Scand. J. Gastroenterol.
, vol.31
, Issue.2
, pp. 126-130
-
-
Hansen, J.M.1
Hallas, J.2
Lauritsen, J.M.3
-
92
-
-
0003699111
-
-
United States Department of Health and Human Services
-
United States Department of Health and Human Services. Health United States. www.cdc.gov/nchs/data/hus/hus08.pdf#
-
Health United States
-
-
-
95
-
-
84855477362
-
-
MHRA
-
MHRA. Ethypharm. www.mhra.gov.uk/home/groups/l-unit1/ documents/websiteresources/con 041375.pdf
-
Ethypharm
-
-
-
99
-
-
84855483443
-
-
23 March
-
Pepcid (Famotidine) Labeling Changes Summary- 23 March 2001. www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm173879.htm
-
(2001)
Pepcid (Famotidine) Labeling Changes Summary
-
-
|